Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
Launch of 20 new medicines expected by 2030
Pivotal OASIS 1 and 2 Phase III studies of investigational compound elinzanetant achieved a statistically significant reduction in frequency and severity of vasomotor symptoms
New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD
Breakthrough Therapy designation for pain associated with DPN granted by FDA
The average time of dilation lasts three to eight hours
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months
Subscribe To Our Newsletter & Stay Updated
